MDL 100,907: A Selective 5‐HT<sub>2A</sub> Receptor Antagonist for the Treatment of Schizophrenia
Tóm tắt
Từ khóa
Tài liệu tham khảo
Baldessarini RJ, 1991, Clozapine, a novel antipsychotic agent, N Eng J Med, 324, 746, 10.1056/NEJM199103143241107
Braff DL, 1995, Gating and habitation deficits in the schizophrenia disorders, Clin Neurosci, 3, 131
Criswell HE, 1993, Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N‐methyl‐D‐aspartic acid antagonist MK‐801 in control and 6‐hydroxydopamine‐lesioned rats, J Pharmacol Exp Ther, 265, 1001
Dewey SL, 1995, Serotonergic modulation of striatal dopaminergic function measured with positron emission tomography and in vivo microdialysis, J Neurosci, 15, 821, 10.1523/JNEUROSCI.15-01-00821.1995
Fadayel GM, 1995, Characterization of the increase in medial prefrontal cortex dopamine release produced in the rat by the putative antipsychotic, MDL 100,907, Abstr Soc Neurosci
Farley IJ, 1980, Receptors for Neurolransmitters and Peptides, 427
GleasonSD ShannonHE.Blockade of phencyclidine‐induced hyperlocomotion by olanzapine clozapine and serotonin subtype selective antagonists in mice (submitted).
Goldstein JM, 1989, Effects of 1CI 169,369, a selective serotonin antagonist, in electrophysiological effects predictive of antipsychotic activity, J Pharmacol Exp Ther, 249, 673
Gouzoulis E, 1994, Psychedelic experiences at the onset of productive episodes of endogenous psychosis, Nervenarzt, 65, 198
Grunder G, 1996, Time course of 5‐HT2A occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography, Neuropsychopharmacology
Gur RE, 1995, Psychopharmacology: The Fourth Generation of Progress, 1185
Halldin C, 1996, [C‐11]MDL 100,907, a radioligand for selective imaging of 5‐HT2A receptors with PET, Abstr Soc Nuclear Med
Hanson GR, 1996, Comparisons of neurotensin responses to MDL 100,907, a selective 5‐HT2A antagonist, with clozapine and haloperidol, Brain Res Bull
Knable MB, 1994, Limbic‐prefrontal connectivity and clozapine, J Clin Psychiatry (Suppl B), 55, 70
Lieberman JA, 1993, Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development, Br J Psychiatry (Suppl), 22, 7, 10.1192/S0007125000292544
LundqvistC HalldinC GinovartN et al.[C‐I1]MDL 100 907 a radioligand for selective imaging of 5‐HT2Areceptors with positron emission tomography (submitted).
Moghaddam BJ, 1994, Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance, Clin Psychiatry, 55, 27
Moser PC, 1996, Reversal of amphetamine‐induced behaviors by MDL 100,907, a selective 5‐HT2A antagonist, Behav Brain Res, 73, 163, 10.1016/0166-4328(96)00090-3
Offord SJ, 1996, Early clinical development of the putative antipsychotic MDL 100,907: A potent and selective 5‐HT2A antagonist, Abstr Am Coll Neuropsychopharmacol
Prisco S, 1994, Serotonin‐dopamine interactions in the rat ventral tegmental area: An electrophysiological study in vivo., J Pharmacol Exp Ther, 271, 83
Robertson GS, 1994, Induction patterns of fos‐like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity, J Pharmacol Exp Ther, 271, 1058
Roth BL, 1994, Binding of typical and atypical antipsychotic agents to 5‐hydroxytrypatamine‐6 and 5‐hydroxytryptamine‐7 receptors, J Pharmacol Exp Ther, 268, 1403
Roth BL, 1995, Psychopharmacology: the Fourth Generation of Progress, 1215
Schmidt CJ, 1990, Selective 5‐hydroxytryptamine‐2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats, J Pharmacol Exp Ther, 255, 478
Schmidt CJ, 1991, 5‐HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4‐methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L‐DOPA, J Pharmacol Exp Ther, 256, 230
Schmidt CJ, 1996, Regional effects of MK‐801 on dopamine release: effects of competitive NMDA or 5‐HT2A receptor blockade, J Pharmacol Exp Ther, 227, 1541
Schreiber R, 1995, (l‐(2,5‐dimethoxy‐4‐iodophenyl)‐2‐aminopropane)‐induced‐head twitches in the rat are mediated by 5‐hydroxytryptamine 5‐HT2A receptors: Modulation by novel 5‐HT2A/2C antagonists, DI antagonists and 5‐HTIA agonists, J Pharmacol Exp Ther, 273, 101
Sipes TE, 1995, DOI disruption of prepulse inhibition of startle in the rat is mediated by 5‐HT2A and not 5‐HT2C receptors, Behav Pharmacol, 6, 839, 10.1097/00008877-199512000-00010
Sorensen SM, 1992, 5‐HT2 receptor antagonists reverse amphetamine‐induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis, J Pharmacol Exp Ther, 260, 872
Sorensen SM, 1993, Characterization of the 5‐HT2 receptor antagonist, MDL 100,907, as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies, J Pharmacol Exp Ther, 266, 684
Giersbergen P, 1996, The Bio‐Clinical Interface
Waters N, 1994, An animal model of schizophrenia based on multivariate analysis of monoaminergic biochemistry and behavior, Abstr Soc Neurosci, 20, 825
Wong DF, 1996, Imaging human cerebral 5‐HT2A receptors with C‐II MDL 100,907, Abstr Soc Nuclear Med
Zhang J, 1994, Influence of excitatory amino acid receptor subtypes on the electro‐physiological activity of dopaminergic and nondopaminergic neurons in rat substantia nigra, J Pharmacol Exp Ther, 269, 313